KAM
Krensavage Asset Management Portfolio holdings
AUM
$189M
This Quarter Return
+1.96%
1 Year Return
+19.71%
3 Year Return
+56.44%
5 Year Return
+120.01%
10 Year Return
+215.64%
AUM
$329M
AUM Growth
+$329M
(+1.7%)
Cap. Flow
+$4.7M
Cap. Flow
% of AUM
1.43%
Top 10 Holdings %
Top 10 Hldgs %
98.39%
Holding
12
New
–
Increased
6
Reduced
6
Closed
–
Top Buys
| 1 |
United Therapeutics
UTHR
|
$2.25M |
| 2 |
Cardinal Health
CAH
|
$1.55M |
| 3 |
Embecta
EMBC
|
$1.25M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
$343K |
| 5 |
Vanda Pharmaceuticals
VNDA
|
$110K |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$505K |
| 2 |
Alkermes
ALKS
|
$169K |
| 3 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
$67K |
| 4 |
Exelixis
EXEL
|
$42.1K |
| 5 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$30.9K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$19.4B
| $49.2M | 14.96% | 177,126 +122 | +0.1% | +$33.9K |
|
|
2
Regeneron Pharmaceuticals
REGN
$61.5B
| $48.9M | 14.84% | 59,488 -615 | -1% | -$505K |
|
|
3
United Therapeutics
UTHR
$13.8B
| $45.3M | 13.75% | 202,110 +10,062 | +5% | +$2.25M |
|
|
4
Exelixis
EXEL
$10.1B
| $41.5M | 12.59% | 2,135,868 -2,171 | -0.1% | -$42.1K |
|
|
5
Alkermes
ALKS
$4.78B
| $39.3M | 11.95% | 1,395,797 -5,986 | -0.4% | -$169K |
|
|
6
Embecta
EMBC
$847M
| $29.9M | 9.07% | 1,062,123 +44,466 | +4% | +$1.25M |
|
|
7
Cardinal Health
CAH
$35.5B
| $26.7M | 8.1% | 353,278 +20,529 | +6% | +$1.55M |
|
|
8
Enanta Pharmaceuticals
ENTA
$180M
| $24.4M | 7.41% | 603,301 +8,483 | +1% | +$343K |
|
|
TARO
9
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $15.6M | 4.74% | 641,910 -2,754 | -0.4% | -$67K |
|
|
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $3.23M | 0.98% | 113,737 -1,088 | -0.9% | -$30.9K |
|
11
Kodiak Sciences
KOD
$478M
| $2.85M | 0.87% | 459,489 -4,109 | -0.9% | -$25.5K |
|
|
12
Vanda Pharmaceuticals
VNDA
$279M
| $2.46M | 0.75% | 361,560 +16,270 | +5% | +$110K |
|